Cargando…
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026098/ https://www.ncbi.nlm.nih.gov/pubmed/36950275 http://dx.doi.org/10.1177/17588359231161409 |
_version_ | 1784909471391154176 |
---|---|
author | Vokes, Natalie I. Pan, Kelsey Le, Xiuning |
author_facet | Vokes, Natalie I. Pan, Kelsey Le, Xiuning |
author_sort | Vokes, Natalie I. |
collection | PubMed |
description | For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers. |
format | Online Article Text |
id | pubmed-10026098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-100260982023-03-21 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer Vokes, Natalie I. Pan, Kelsey Le, Xiuning Ther Adv Med Oncol Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options. This article reviews the clinical data on ICIs for each of the driver oncogene defined lung cancer subtypes, including efficacy, both for ICI as monotherapy or in combination with chemotherapy or radiation; toxicities from ICI/targeted therapy in combination or in sequence; and potential strategies to enhance ICI efficacy in oncogene-driven non-small-cell lung cancers. SAGE Publications 2023-03-18 /pmc/articles/PMC10026098/ /pubmed/36950275 http://dx.doi.org/10.1177/17588359231161409 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions Vokes, Natalie I. Pan, Kelsey Le, Xiuning Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer |
title | Efficacy of immunotherapy in oncogene-driven non-small-cell lung
cancer |
title_full | Efficacy of immunotherapy in oncogene-driven non-small-cell lung
cancer |
title_fullStr | Efficacy of immunotherapy in oncogene-driven non-small-cell lung
cancer |
title_full_unstemmed | Efficacy of immunotherapy in oncogene-driven non-small-cell lung
cancer |
title_short | Efficacy of immunotherapy in oncogene-driven non-small-cell lung
cancer |
title_sort | efficacy of immunotherapy in oncogene-driven non-small-cell lung
cancer |
topic | Controversies in Immunotherapy for Patients with Lung Cancer: Pragmatic Solutions |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026098/ https://www.ncbi.nlm.nih.gov/pubmed/36950275 http://dx.doi.org/10.1177/17588359231161409 |
work_keys_str_mv | AT vokesnataliei efficacyofimmunotherapyinoncogenedrivennonsmallcelllungcancer AT pankelsey efficacyofimmunotherapyinoncogenedrivennonsmallcelllungcancer AT lexiuning efficacyofimmunotherapyinoncogenedrivennonsmallcelllungcancer |